NEW YORK - Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) shares tumbled 18.5% after the company reported third quarter earnings that missed analyst expectations and lowered its full-year revenue guidance.
The biotechnology company posted Q3 revenue of $65.2 million, falling short of the $67.55 million consensus estimate. Adjusted earnings per share came in at -$0.02, $0.01 worse than analysts expected. Maravai also reported a net loss of $176.0 million for the quarter, which included a $154.2 million goodwill impairment charge.
In a concerning development for investors, Maravai reduced its full-year 2024 revenue guidance to a range of $255.0 million to $265.0 million, below the previous analyst consensus of $275.3 million. The midpoint of the new guidance range represents a 6% decrease from prior expectations.
"We achieved significant milestones this quarter, launching innovative new products across the portfolio," said CEO Trey Martin. However, he noted that "The mRNA, Gene Editing and cell and gene therapy markets continue to evolve rapidly."
Despite the weak results, Maravai highlighted several positive developments, including commencing its first mRNA contract for a customer's Phase II clinical trial at its Flanders 2 GMP manufacturing facility. The company also strengthened its patent portfolio and introduced new product offerings.
Maravai announced plans to acquire the DNA and RNA business of Officinae Bio, a deal expected to close in early 2025. The acquisition aims to expand Maravai's capabilities in developing nucleic acid-based therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.